Vericel Celebrates FDA Approval for Pediatric Use of NexoBrid, Expanding Treatment Horizons for Severe Thermal Burns...
Vericel Announces FDA Approval of NexoBrid for Pediatric Severe Thermal Burns, Expanding Target Customer Base to Include Pediatric Burn Centers In a landmark achievement, Vericel Corporation (NASDAQ: VCEL) has announced...
Aug 15, 2024
• Biotechnology & Pharmaceuticals Industry
Clinical Study
